A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

The main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD'). Another aim is to learn how well treatment of brentuximab vedotin plus AVD works. All participants will receive brentuximab vedotin plus AVD for approximately 6 months. Participants will undergo tests like Echocardiography (ECHO) and pulmonary function testing (PFT) during the study. ECHO is a test that uses ultrasound to show how the heart muscle and valves are working; PFT is a te

Trial Details

NCT ID
NCT06831370
Phase
PHASE4
Sponsor
Takeda
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Brentuximab Vedotin
  • Doxorubicin
  • Vinblastine
  • Dacarbazine
Locations (sample)
  • Vijayawada, Andhra Pradesh, India|16.50745,80.6466
  • Guwahati, Assam, India|26.1844,91.7458
  • Surat, Gujarat, India|21.19594,72.83023
  • Bangalore, Karnataka, India|12.97194,77.59369
  • Puducherry, Kerala, India

Key Eligibility Criteria

  • Treatment-naïve, Hodgkin lymphoma (HL) participants with Ann Arbor Stage 3 or 4 disease.
  • Note: Participants must have histologically confirmed classical HL according to the current world health organization classification.
  • Participants must have bidimensional measurable disease as documented by radiographic technique (spiral computed tomography \[CT\] preferred) per t…
  • Male or female participants 18 years or older.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →